The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of TGW101 in patients with advanced solid tumors.
 
Anthony Tolcher
Employment - Next Oncology
Leadership - Next Oncology
Stock and Other Ownership Interests - Immunome; Pyxis (Inst)
Consulting or Advisory Role - AbbVie (Inst); Aclaris Therapeutics (Inst); Adagene (Inst); Affinia Therapeutics (Inst); Agenus (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bright Peak Therapeutics (Inst); Coretag Therapeutics (Inst); Cullinan Oncology (Inst); Curadev Pharma, Inc. (Inst); Daiichi Sankyo, Inc. (Inst); Day One Biopharmaceuticals, Inc., (Inst); Deka Biosciences (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Exelixis (Inst); FibroGen (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); HEXAGON BIO, INC. (Inst); HiberCell (Inst); Horizon CME (Inst); IDEA Pharma (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Immuneering (Inst); Immunome (Inst); Immunomet (Inst); Immuto Scientific (Inst); IMPAC Medical Systems (Inst); Indupro Inc (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Karma Oncology (Inst); Kirilys Therapeutics (Inst); Kivu Bioscience (Inst); Leerink (Inst); Lengo Therapeutics (Inst); Lilly (Inst); Link Immunotherapeutics (Inst); Medicxi (Inst); Mekanistic Therapeutics (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Merck KGaA (Inst); Mersana (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Mythic Therapeutics, Inc (Cytel) (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nerviano Medical Sciences (Inst); Nested Therapeutics (Inst); Novo Nordisk (Inst); Novo Ventures (Inst); Nurix (Inst); Ocellaris Pharma (Inst); Partner Therapeutics (Inst); Pfizer (Inst); Pheon Therapeutics (Inst); Pierre Fabre (Inst); Praxia Precision Medicines (Inst); Praxis Precision Medicines (Inst); Prelude Therapeutics (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Pyramid Biosciences (Inst); Pyxis (Inst); Qualigen Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Senti Biosciences (Inst); Singzyme Pte Ltd (Inst); Singzyme Pte Ltd (Inst); SK Life Sciences (Inst); Sotio (Inst); Spirea (Inst); Spirea Limited Inc. (Inst); Stratus Therapeutics Inc (Inst); Sun Pharma Advanced Research Company (Inst); Tagworks Pharmaceuticals (Inst); Tensegrity Pharma, Inc (Inst); TheraTechnologies (Inst); Transcenta (Inst); Transgene (Inst); Trillium Therapeutics (Inst); Tubulis GmbH (Inst); Venus Oncology (Inst); Verastem (Inst); VIDA VENTURES ADVISORS, LLC (Inst); Vincerx Pharma (Inst); Vincerx Pharma (Inst); Voyant Bio (Ask Mendel AI Inc) (Inst); VRise Therapeutics (Inst); Zentalis (Inst); ZielBio (Inst)
Research Funding - AbbVie (Inst); ABL Bio (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Apros Therapeutics (Inst); Arcellx (Inst); ARMO BioSciences (Inst); Arrys Therapeutics (Inst); Artios (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Bioinvent (Inst); Birdie (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); CStone Pharmaceuticals (Inst); Daiichi Sankyo, Inc. (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ImmuneOncia (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Naturewise (Inst); NBE Therapeutics (Inst); NextCure (Inst); Nitto BioPharma (Inst); Odonate Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Qilu Puget Sound Biotherapeutics (Inst); Samumed (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
Patents, Royalties, Other Intellectual Property - Ascentage Pharma; Zentails
Expert Testimony - Immunogen
Travel, Accommodations, Expenses - Sotio (Inst)
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Lilly; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; lepu biopharma (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Tango Therapeutics (Inst)
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - AstraZeneca; Becton Dickinson; Biocartis; Calibr; Cybrexa Therapeutics; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Debiopharm Group; eFFECTOR Therapeutics; Elevation Oncology; Exelixis; Go Therapeutics; GT Aperion; Guardant Health; Harbinger Health; Illumen; Incyte; Jazz Pharmaceuticals; Kivu Biosciences; Lengo Therapeutics; LigaChem Biosciences; Loxo/Lilly; Menarini Group; Mersana; Molecular Templates; OnCusp Therapeutics; Protai; Ribometrix; Sanofi; Seagen; SystImmune; Tallac Therapeutics; Tempus; Theratechnologies; Vir Biotechnology; Zentalis; Zymeworks
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); PUMA Biotechnology (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC); Physicans' Education Resource
 
Michael Gordon
Stock and Other Ownership Interests - Remepy; Sphinx HS (previously CAREMISSION)
Consulting or Advisory Role - Deciphera; Imaging Endpoints; Morphic Therapeutic; OnQuality Pharmaceuticals; Qualigen Therapeutics; SpringWorks Therapeutics; Viracta Therapeutics
Research Funding - Abbvie (Inst); Agenus (Inst); Arcus Biosciences (Inst); Corcept Therapeutics (Inst); Deciphera (Inst); DynamiCure Biotechnology (Inst); Fore Biotherapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); ImaginAb (Inst); Merck Serono (Inst); NiKang Therapeutics (Inst); Nimbus Therapeutics (Inst); Novartis (Inst); OncoResponse (Inst); Pfizer (Inst); Pionyr (Inst); Plexxikon (Inst); Pyxis (Inst); Revolution Medicines (Inst); Riboscience (Inst); Shenzen Ionova (Inst); Sirnaomics (Inst); SQZ Biotech (Inst); Syndax (Inst); TAGWORKS (Inst); Theseus Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Veru (Inst)
Patents, Royalties, Other Intellectual Property - Application Serial No.: PCT/US24/27766 Filing Date: May 3, 2024 Title: Planet atmosphere gases enwrapped into composite nanomaterials with medical treatment applications
Travel, Accommodations, Expenses - Agenus
 
Anthony Olszanski
Consulting or Advisory Role - Anaveon; Bristol-Myers Squibb; IO Biotech; Replimune; Signatera
Research Funding - Anaveon (Inst); Antengene (Inst); Clasp (Inst); Clasp (Inst); GlaxoSmithKline (Inst); Immatics (Inst); Lantern Pharma (Inst); Lilly (Inst); Normunity (Inst); Regeneron (Inst); Replimune (Inst); Shionogi (Inst); Solve (Inst); Tagworks (Inst); Takeda (Inst); Viewpoint Molecular Targeting (Inst)
 
Samuel Klempner
Honoraria - Merck Serono
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; BeiGene; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; EsoBiotec; Gilead Sciences; I-Mab; Merck; Novartis; Taiho Oncology
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); BeiGene (Inst); I-Mab (Inst); Leap Therapeutics (Inst); Mersana (Inst)
Other Relationship - Clinical Care Options; NCCN; Research to Practice
(OPTIONAL) Uncompensated Relationships - Debbies Dream Foundation
 
Marc Robillard
Employment - Tagworks Pharmaceuticals, B.V.
Leadership - Tagworks Pharmaceuticals, B.V. (Inst)
Stock and Other Ownership Interests - Tagworks Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Tagworks Pharmacueticals, B.V.
 
Keith Orford
Employment - Parabilis Medicines; Tagworks Pharmaceuticals, B.V.
Leadership - Parabilis Medicines; Tagworks Pharmaceuticals, B.V.
Stock and Other Ownership Interests - Tagworks Pharmaceuticals B.V.
Patents, Royalties, Other Intellectual Property - FOGPharma; Parabilis Medicines
 
Shiraj Sen
Consulting or Advisory Role - Bayer; Guardant Health
Travel, Accommodations, Expenses - Bayer; Guardant Health